AndhraNews.net
Home » Features » Health » Deep Vein Thrombosis

Deep Vein Thrombosis


About Deep Vein Thrombosis (DVT)

A study says that office workers who sit at a desk for eight hours a day and spend more than three hours without stretching double their risk of developing DVT.

Deep Vein Thrombosis in News

Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Business Wire India

Indraprastha Apollo Hospitals Organises the 7th Asia Pacific Vascular Intervention Course
Business Wire IndiaThe 7th Asia Pacific Vascular Intervention Course, under the aegis of Indraprastha Apollo Hospital, New Delhi, was organized in association with International Society of Endovascular Specialists, USA at The Oberoi, New Delhi from 12th to 14th June, 2015

Curb Energy Consumption
(Family Features) Water heaters are energy intensive appliances. In fact, they are the second largest energy user in the home, and as they age, they become less efficient, requiring even more energy.

DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2015 Results
RALEIGH, NC--(Marketwired - August 10, 2015) - DARA BioSciences, Inc

DARA BioSciences Announces Stockholder Approval of Merger With Midatech
RALEIGH, NC--(Marketwired - December 02, 2015) - DARA BioSciences, Inc

DARA BioSciences Announces Third Quarter 2015 Results
RALEIGH, NC--(Marketwired - November 02, 2015) - DARA BioSciences, Inc

DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015
RALEIGH, NC--(Marketwired - October 06, 2015) - DARA BioSciences, Inc. (NASDAQ: DARA) today announced that it will be featured as a presenting company at the 2015 Aegis Growth Conference, sponsored by Aegis Capital Corp

DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush
DARA's Salesforce to Launch Oravig Into Oncology Market, While Marketing Partner, Mission Pharmacal, Launches Into the Primary Care Market; Over 28 Million Prescriptions Filled Annually for Oral Thrush in the U.S.

DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
RALEIGH, NC--(Marketwired - September 23, 2015) - DARA BioSciences, Inc

Compression Therapy Market Worth $3.96 Billion by 2022: Grand View Research, Inc.
The global compression therapy market size is expected to reach USD 3.96 billion by 2022, according to a new report by Grand View Research Inc. Increasing prevalence of chronic venous disorders such as deep vein thrombosis, leg ulcers, lymphedema and venous insufficiency is expected to serve as the key driver.

New Women's Health Initiative Launches to Increase Risk Awareness and Reduce Deaths Connected to Life-Threatening Blood Clots
The National Blood Clot Alliance (NBCA), in partnership with the Alexandra L. Rowan Memorial Foundation, is launching a new and unique women's health initiative, focused on the continuum of blood clotting risks that confront women throughout their lifetime

DARA BioSciences Announces Second Quarter 2015 Results
RALEIGH, NC--(Marketwired - August 12, 2015) - DARA BioSciences, Inc

DARA BioSciences Announces Proposed Acquisition Agreement With Midatech Pharma PLC, a UK Based Specialty Pharmaceutical Company
RALEIGH, NC--(Marketwired - June 04, 2015) - DARA BioSciences, Inc

DARA BioSciences Announces First Quarter 2015 Results
RALEIGH, NC--(Marketwired - May 13, 2015) - DARA BioSciences, Inc

Strata Partners With Yale New Haven Health System to Reduce Cost by Improving Quality

National Blood Clot Alliance Unveils New Public Education Campaign Urging the Public to Learn About Blood Clot Risks

DARA BioSciences Announces the Acquisition of Exclusive North American Rights to Oravig(R) (Miconazole Buccal Tablets 50mg), From Onxeo S.A.
RALEIGH, NC--(Marketwired - March 10, 2015) - DARA BioSciences, Inc

DARA BioSciences Announces Participation at the 27th Annual ROTH Conference in Laguna Niguel, California
RALEIGH, NC--(Marketwired - March 05, 2015) - DARA BioSciences, Inc

Dara BioSciences Announces Fourth Quarter and Full Year 2014 Results
RALEIGH, NC--(Marketwired - March 03, 2015) - DARA BioSciences, Inc

Hansen Medical Announces Completion of World's First Intravascular Robot-Assisted IVC Filter Retrieval
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced the completion of the world's first intravascular robot-assisted retrieval of an Inferior Vena Cava (IVC) Filter. Dr

Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant

A Complex Angioplasty, Stenting of Blocked Aorta in Abdomen Done to Yemen Woman by JIVAS doctors in Bhagwan Mahaveer Jain Hospital, Bangalore
A team of doctors, led by Dr. K.R. Suresh at Jain Institute of Vascular Science (JIVAS) A Unit of Bhagwan Mahaveer Jain Hospital, Bangalore, successfully performed a minimally invasive endovascular procedure i.e. angioplasty and stenting of the blocked aorta in the abdomen and to both legs. This was performed with small incisions in both the thighs and from left arm

Covidien Promotes Greater Global Awareness of Thrombosis Risks
As part of a global effort to highlight the threat posed by venous thromboembolism (VTE), Covidien plc today announced it will support the inaugural World Thrombosis Day campaign as a Global Partner

New Pradaxa® data to be presented at the ESC Congress 2014
For Non-US/Non-UK/Non-Canadian Media

Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate

Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
Boehringer Ingelheim today announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).1 The U.S. Food and Drug Administration (FDA) approved Pradaxa® for DVT and PE patients earlier this year


TEMPE, AZ--(Marketwired - December 29, 2014) - New Top-10 listings from American Traffic Solutions (ATS), the nation's leading provider of road safety cameras, names the Honda Accord as the most frequent make and model of vehicle caught running red lights in 2014, and finds most red-light runners were driving vehicles painted gray.

DARA BioSciences Announces Date and Time for Announcement of Third Quarter 2014 Results
RALEIGH, NC--(Marketwired - October 29, 2014) - DARA BioSciences, Inc

DARA BioSciences Announces Third Quarter 2014 Results
RALEIGH, NC--(Marketwired - November 05, 2014) - DARA BioSciences, Inc

DARA BioSciences Continues to Support Patient Outreach and Education in Conjunction With Breast Cancer Awareness Month
RALEIGH, NC--(Marketwired - October 31, 2014) - DARA BioSciences, Inc

DARA BioSciences Petitions FDA to Amend Label for Tamoxifen Citrate and Soltamox® to Extend Duration of Adjuvant Therapy to 10 Years
RALEIGH, NC--(Marketwired - October 29, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals with a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today petitioned the U.S

DARA BioSciences Supports Breastcancer.org to Increase Awareness and Raise Funds to Fight Breast Cancer
RALEIGH, NC--(Marketwired - October 24, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced it is supporting Breastcancer

DARA BioSciences Product Gelclair(R) Attains Market Leadership Position in U.S. Retail Market
RALEIGH, NC--(Marketwired - October 14, 2014) - DARA BioSciences, Inc

Midwest Medical Enterprises Introduces Innovative Medical Device
Midwest Medical Enterprises (MME), a medical device company headquartered in Atlanta, has announced a new division, DVTlite, as the exclusive U.S. provider of the revolutionary mobile compression device, the Venowave.

DARA BioSciences Announces Participation at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10, 2014
RALEIGH, NC--(Marketwired - September 03, 2014) - DARA BioSciences, Inc

DARA BioSciences Announces Second Quarter 2014 Results
RALEIGH, NC--(Marketwired - August 12, 2014) - DARA BioSciences, Inc

NuVasive(R) to Participate in the 21st Annual International Meeting on Advanced Spine Techniques (IMAST)
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce its participation at the 21st International Meeting on Advanced Spine Techniques (IMAST) from Wednesday, July 16 to Friday, July 18, 2014, in booth #6 at the Valencia Convention Centre in Valencia, Spain.

Alexander Rosenau, DO, FACEP, President of the American College of Emergency Physicians, to Keynote 12th Annual Advanced Emergency & Acute Care Medicine Conference
Alexander Rosenau, DO, FACEP, president of the American College of Emergency Physicians (ACEP), will be the keynote speaker at the 12th Annual Emergency and Acute Care Medicine Conference. The conference will be held Sept. 8-11 at the Sheraton Atlantic City Convention Center Hotel in Atlantic City, N.J.

DARA BioSciences Announces Leadership Transition
RALEIGH, NC--(Marketwired - June 17, 2014) - DARA BioSciences, Inc

DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma
RALEIGH, NC--(Marketwired - June 16, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, today announced the U.S

New data on safety and efficacy of Pradaxa® in treatment of acute deep vein thrombosis and pulmonary embolism
For media outside of the US, the UK & Canada only

Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim’s innovation promise in cardiovascular diseases

ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations
For media outside of the US, the UK & Canada only

Celgene Will Discontinue Phase III ORIGIN® Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Celgene Corporation (NASDAQ: CELG) today announced that after consultation with the U.S. Food and Drug Administration (FDA) Celgene will discontinue treatment with REVLIMID® (lenalidomide) in the open-label, phase III ORIGIN® trial, which enrolled 450 patients in over 100 sites in 26 countries

Application submitted to the European Medicines Agency (EMA) for use of Pradaxa® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE
For media outside of the U.S., the UK & Canada only

CLOTS 3 Study Delivers Lifesaving Results Using Covidien’s Blood Clot Prevention Technology
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien’s Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients.

Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease
Celgene International Sàrl (NASDAQ: CELG) was today notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID®

U.S. Food and Drug Administration Approves REVLIMID® (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
Celgene Corporation (NASDAQ: CELG) has announced the U.S

New findings from two studies support substantial benefit of Pradaxa® for prevention of recurrent deep vein thrombosis and pulmonary embolism
For Non-US, Non-UK & Non-Canadian Media Only

Celgene Provides REVLIMID® Regulatory Update

Alchemia Reports Record Fondaparinux Quarterly Profit Share
A$3.9m profit share for quarter ending 30 June 2013 Total Alchemia fondaparinux profit share of A$9.6m for FY 2013 Fondaparinux approved in Canada with launch expected soon Australian drug discovery and development company Alchemia Limited (ASX: ACL) today announced a record quarterly profit share of A$3.9 million (US$3

Alchemia Limited Provides Company Update
$2

Alchemia Announces Multi-Target Drug Discovery Collaboration With AstraZeneca on VAST Discovery Platform
Alchemia Limited (ASX: ACL)

Kaleidoscope Medical Secures Series A Funding
Kaleidoscope Medical LLC, a medical device company developing innovative solutions for treating venous thromboembolic disease (VTE), announced today that it has closed its Series A financing. Proceeds will be used to advance the company's revolutionary inferior vena caval (IVC) filter through regulatory clearance

Alchemia Announces Addition of Two Board Members
Australian drug discovery and development company Alchemia Limited (ASX: ACL) has appointed two additional non-executive directors (NEDs) to its Board as part of a larger board realignment reflecting the importance of the North American and European markets. Dr. Susan Kelley and Mr. Nathan Drona have agreed to take NED Board positions, effective immediately.

Global Anticoagulants Market to Spike to Over $24 Billion by 2019
TriMarkPublications.com cites in its newly published "New Oral Anticoagulants Markets" report that the global anticoagulants market will spike to over $24 billion by 2019. For more information, visit: http://www.trimarkpublications.com/new-oral-anticoagulants-markets/.

Alchemia Granted Key US Patent
Brisbane based drug discovery and development company Alchemia Limited (ASX: ACL) has been granted a key US patent critical to its platform oncology technology.

Alchemia Completes Enrolment in Pivotal Phase III HA-Irinotecan Trial of Metastatic Colorectal Cancer
415 patients recruited; recruitment now closed Participation in sub-study outperformed expectations Results expected early 2014 Brisbane drug discovery and development company Alchemia Limited (ASX: ACL) has completed enrolment of patients in a pivotal Phase III clinical trial evaluating its lead product, HA-Irinotecan, for the treatment of metastatic colorectal cancer

Alchemia Achieves $3.4 Million Quarterly Fondaparinux Profit Share
profit share up over 90% on last quarter market share increased to 25% from 22% cost of goods significantly improved Alchemia Limited (ASX: ACL) has recorded a quarterly profit share of $3.4 million on sales of its generic anti-coagulant product fondaparinux, an increase of over 90% from the previous quarter. The profit share results from total net sales of $12.3 million

Alchemia Appoints Charles Walker as Chief Executive Officer
Brisbane drug discovery and development company Alchemia Limited (ASX: ACL) announced that Charles Walker has been appointed to the position of Chief Executive Officer.

New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session
For Non-US, Non-UK & Non-Canadian Media Only

Eating lunch at your desk may up risk of blood clots by 2-fold
If you're eating lunch at your desk, you could double the chances of developing a fatal blood clot, experts have warned.

Equity Briefing : GNOM, AFFY and MRK are Notable Gainers in Healthcare
Major U.S. stock indices pared most of its early losses and now trading near to session high after ending sharply lower in yesterday's session as few Few Fed officials thought of another round of quantitative easing. There are several healthcare stocks which are showing notable headlines in today's session.Affymax, Inc

Alchemia to Present at the Cowen Health Care Conference
Alchemia Limited, Inc (ASX: ACL), today announced that Peter Smith, Alchemia's Chief Executive Officer, is scheduled to present at the 32nd Annual Cowen Health Care Conference in Boston on Monday, March 5, 2012 from 4:30-4:55 PM EST.

Alchemia Recruits First Patient to Pivotal Phase III Clinical Trial of HA-Irinotecan in Metastatic Colorectal Cancer
(ASX: ACL) -- Alchemia Limited is pleased to announce that the first patient in the pivotal Phase III clinical study of its lead cancer drug, HA-Irinotecan, was randomized on Dec 30, 2011 and has now received their first cycle of treatment.

Non-oral contraceptives up risk of serious blood clots
A new study has put more weight to the evidence that certain non-oral hormonal contraceptives (e.g. skin patches, implants and vaginal rings) carry a higher risk of serious blood clots (known as venous thromboembolism) than others.

Snorers at triple risk of fatal blood clot
Snorers are three times more likely to develop a potentially fatal blood clot as compared to non-snorers, according to a new study.

Aspirin 'may thwart DVT and PE in joint replacement patients'
Following a total joint replacement, anticoagulation drugs can prevent Deep Vein Thrombosis (DVT) or pulmonary embolism (PE), a new study has revealed.

Why you should not opt for window seat during long flight
Oral contraceptives, sitting in a window seat, advanced age, and pregnancy increases risk of a deep vein thrombosis (DVT), or blood clot in long-distance travellers, a new study has warned.

Iron supplements could prevent life-threatening blood clots
A new research has indicated that iron supplements could be used to prevent deep vein thrombosis and other life-threatening blood clots.

Drospirenone-containing birth control pills ups risk of blood clots
A new study has found that the use of drospirenone-containing oral birth control pills significantly increases the risk of blood clots, both deep vein thrombosis and pulmonary embolism.

New contraceptive pills 'likelier to double blood clot risk'
A U.S. study has found that newer brands of contraceptive pill may increase more than double the risk of dangerous blood clots compared with older types.

Dangerous, deep blood clots should be treated aggressively: Docs
The American Heart Association is urging doctors to consider therapies in addition to blood thinners to treat certain patients with potentially dangerous blood clots that form in the deep veins and travel to the lungs.

LawyersandSettlements.com Releases Its Top 10 Pharmaceutical Topics for 2011
LawyersandSettlements.com, the premier publication for Online Legal Media, today released its list of the hottest consumer-related pharmaceutical legal news stories for its readership during the last year.

Young Brit dies following 12-hr continuous Xbox session
A 20-year-old British guy was killed by a blood clot after he kept playing his 'Xbox' for almost 12 hours at a stretch.

ELIQUIS® (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement
The European Commission has approved ELIQUIS® in the 27 countries of the European Union (EU) for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery

New drugs show promise in treating dangerous blood clots
Scientists have suggested that two new drugs - Apixaban and Rivaroxaban - might be more effective and easier to use than commonly used medicines in preventing dangerous blood clots after hip replacement surgery.

Exercise may benefit patients with deep vein thrombosis
A six-month exercise training program designed to increase leg strength, leg flexibility and overall fitness may improve post-thrombotic syndrome, a frequent, chronic complication of deep vein thrombosis, suggests a new study.

Comment on this story

Share